Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

Annexon, Inc.9 enrolled

Overview

This is a multi center, open-label, single dose, safety study. Approximately 9 to 15 participants with open-angle glaucoma are assigned into 3 sequential dose-levels and will receive ANX007 administered as single, IVT injections.

This is a phase 1, open-label, dose-escalation, safety study evaluating up to 3 dose levels of ANX007 administered as single IVT injections. Approximately 9 to 15 eligible participants are enrolled into one cohort each. All participants receive ANX007 in an open-label manner. The primary objective is to evaluate the safety and tolerability of a single intravitreal (IVT) injection of ANX007 in participants with primary open-angle glaucoma. Secondary objectives are to evaluate the serum pharmacokinetics (PK) and immunogenicity. An exploratory objective will evaluate the pharmacodynamic (PD) effect of ANX007 on serum C1q activity.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Open-angle Glaucoma

Interventions

ANX007BIOLOGICAL

Single ascending dose

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female age 18 years and older * Diagnosis of primary open-angle glaucoma * Intraocular pressure \<21 mm Hg on a stable IOP treatment regimen * Reliable visual field testing Exclusion Criteria: * BCVA worse than 20/80 in either eye * Extensive glaucomatous visual-field damage * History of intraocular inflammatory or infectious eye disease in study eye * Ocular trauma in study eye within the preceding 6 months * History of uncomplicated cataract surgery less than 6 mos prior * Any abnormality preventing reliable Tonopen tonometry in study eye * Active malignancy within past 5 yrs * Previous tx with another humanized monoclonal antibody * History of any autoimmune or neurologic disease * Concurrent use of glucocorticoid medications * Receiving monoamine oxidase inhibitor therapy

Locations (1)

Eye Research Foundation

Newport Beach, California, United States

Outcomes

Primary Outcomes

Safety and tolerability as measured by the occurrence of adverse events

Time frame: Day 56

Secondary Outcomes

Serum plasma concentration of ANX007 after a single IVT injection.

Time frame: Day 15

Immunogenicity of ANX007 after a single IVT injection.

Time frame: Day 56

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.